You are using an outdated browser. Please upgrade your browser to improve your experience and security.

What is AML?

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. In AML, the bone marrow makes abnormal red blood cells, platelets, or myeloblasts (a type of immature white blood cell). These abnormal cells are called “blasts” and are the leukemia cells. These cells divide quickly, leaving less room for healthy cells to develop, and also cause the disease to spread fast. Acute leukemia is monitored by measuring the number of blasts in the bone marrow.

View more AML facts.
 
Bone Marrow From Healthy Patient and AML Patient part 1 of 6

Bone marrow from
healthy person

Bone Marrow From Healthy Patient and AML Patient part 2 of 6

Bone marrow from
person with AML

Bone Marrow From Healthy Patient and AML Patient part 3 of 6

Red blood cell

Platelet part 4 of 6

Platelet

Bone Marrow From Healthy Patient and AML Patient part 5 of 6

White blood cell

Bone Marrow From Healthy Patient and AML Patient part 6 of 6

Leukemia cell

The video below will teach you more about AML and how it develops in the body.

WHAT IS VYXEOS?

VYXEOS is an intravenous (IV) chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.